Teleflex Incorporated (NYSE: TFX), a leading global provider of
medical technologies, today announced it was awarded two group
purchasing agreements with Premier, Inc. Effective July 1, 2024,
the Premier National Hemostasis Products and SURPASS® Hemostasis
Products agreements allow Premier members, at their discretion, to
take advantage of special pricing and terms pre-negotiated by
Premier for Teleflex products within the hemostatic portfolio.
Premier’s SURPASS® program is designed to drive the
highest-level commitment and savings for members through aggregated
purchasing of high-quality products and services. The program
brings together Premier’s most committed members to coordinate
purchasing decisions and maintain standardization across their
facilities. By providing additional value to Premier contracted
suppliers through volume and commitment, the program is expected to
achieve best-in-market pricing.
QuikClot™ Hemostatic Dressings and Devices control bleeding
faster than standard gauze or laparotomy pads,1-3 enabling
clinicians to move patients to the next stage of care quickly. The
portfolio includes a range of products to support clinicians
throughout the hospital, including in the Emergency Department,
Operating Room, Intensive Care Unit, and Catheterization Lab.
“QuikClot™ Hemostatic Dressings and the QuikClot Control+™
Hemostatic Device are critical tools to aid bleeding control and
the blood loss mitigation efforts of acute care clinicians,” said
Kevin Robinson, President and General Manager, Anesthesia and
Emergency Medicine at Teleflex. “We are pleased to support Premier
members with these new Hemostasis product agreements and provide
clinicians with medical devices that help improve the health and
quality of people’s lives.”
The Teleflex hemostasis portfolio also includes
D-Stat™ Flowable Hemostat, D-Stat™ Dry Topical Hemostat,
Thrombix™ Topical Hemostat, Thrombix™ Topical Hemostat
Silver, and ThrombiDisc™ Topical Hemostat. This portfolio
provides Interventional Cardiology and Radiology clinicians with
options that address their patient’s bleeding scenarios from
abrasions to traumatic injuries.
Premier is a leading healthcare improvement company, uniting an
alliance of approximately 4,350 U.S. hospitals and 300,000 other
providers to transform healthcare. With integrated data and
analytics, collaboratives, supply chain solutions, and consulting
and other services, Premier enables better care and outcomes at a
lower cost.
About Teleflex IncorporatedAs a global provider
of medical technologies, Teleflex is driven by our purpose to
improve the health and quality of people's lives. Through our
vision to become the most trusted partner in healthcare, we offer a
diverse portfolio with solutions in the therapy areas of
anesthesia, emergency medicine, interventional cardiology and
radiology, surgical, vascular access, and urology. We believe that
the potential of great people, purpose-driven innovation, and
world-class products can shape the future direction of
healthcare.
Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™,
Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands
united by a common sense of purpose. At Teleflex, we are empowering
the future of healthcare. For more information, please visit
teleflex.com.
Forward-Looking StatementsAny statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements. Any
forward-looking statements contained herein are based on our
management's current beliefs and expectations, but are subject to a
number of risks, uncertainties and changes in circumstances, which
may cause actual results or company actions to differ materially
from what is expressed or implied by these statements. These risks
and uncertainties are identified and described in more detail in
our filings with the Securities and Exchange Commission, including
our Annual Report on Form 10-K.
References:1. Causey MW, McVay DP, Miller S, et
al. J Scientific Research. 2012; 177 (2): 301-305. Pre-clinical
study. 2. Trabattoni D, Montorsi P, Fabbiocchi F, et al. Eur
Radiol. 2011; 21: 1687- 16913. Data on file at Teleflex.
Comparative data may not be indicative of clinical performance.
Rx Only.CAUTION: Federal (USA) law restricts this device to sale
by or on the order of a physician.Refer to package insert for
complete warnings, indications, contraindications, precautions,
potential complications and Instructions For Use.
QuikClot Hemostatic Dressing is intended for use as a topical
dressing for local management of bleeding wounds such as cuts,
lacerations and abrasions. It may also be used for temporary
treatment of severely bleeding wounds such as surgical wounds
(operative, postoperative, dermatological, etc.) and traumatic
injuries.
The QuikClot Control+™ Hemostatic Device is indicated for
temporary control of internal organ space bleeding for patients
displaying class III or IV bleeding. It may also be used for
control of severely bleeding wounds such as surgical wounds and
traumatic injuries.Cardiac surgical procedures: for temporary
control of mild and moderate bleeding in cardiac surgical
procedures, as well as in patients displaying class III or class IV
bleeding. Bone surfaces following sternotomy: to control bleeding
from bone surfaces following a sternotomy
Teleflex, the Teleflex logo, Arrow, Barrigel, Deknatel, D-Stat,
LMA, Pilling, QuikClot, QuikClot Control+, Rüsch, Thrombix,
ThrombiDisc, UroLift, and Weck are trademarks or registered
trademarks of Teleflex Incorporated or its affiliates, in the U.S.
and/or other countries.© 2024 Teleflex Incorporated. All rights
reserved. MC-009903
Contact:TeleflexLawrence KeuschVice President,
Investor Relations and Strategy
Developmentinvestor.relations@teleflex.com610-948-2836
Grafico Azioni Teleflex (NYSE:TFX)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Teleflex (NYSE:TFX)
Storico
Da Dic 2023 a Dic 2024